NCT04841967

Brief Summary

A radical paradigm shift is taking place where technology, notably the explosion in easy accessible direct-to-consumer genetic testing (e.g., 23andMe) and a high consumer interest in genealogy (e.g., Ancestry.com), has hijacked gamete (eggs, sperm) and embryo donation recipient parents' control over whether to inform their children about their donor conception. Historically, the practice of gamete donation has been shrouded in secrecy, however, the skyrocketing use of direct-to-consumer genetic testing means that at any point in an adult life, an uninformed donor-conceived person can learn their DNA does not match their presumed ancestry of their parents and family members, putting into question their genetic relatedness to their parents and launching a spiraling sequence of negative health consequences and trauma. Furthermore, the lack of one's knowledge about actual genetic heritage in the age of precision medicine can be enormously detrimental to health and can result in medical maltreatment, including death. To address this serious problem and in accordance with International Patient Decision Aid Standards, we developed a digital, tailored, multicomponent Tool to Empower ParentaL TeLling and Talking (i.e., TELL Tool). The objective of this R34 study is to examine the feasibility, acceptability, and preliminary effects of the TELL Tool intervention in a pilot randomized-controlled feasibility trial with 60 donor-recipient parents and 10 clinicians to determine intervention viability and inform a larger, efficacy trial. An eBook with content about good parenting principles serves as the attention control.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
75

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jul 2021

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 8, 2021

Completed
4 days until next milestone

First Posted

Study publicly available on registry

April 12, 2021

Completed
4 months until next milestone

Study Start

First participant enrolled

July 26, 2021

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2022

Completed
10 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 31, 2023

Completed
5 months until next milestone

Results Posted

Study results publicly available

January 11, 2024

Completed
Last Updated

January 11, 2024

Status Verified

January 1, 2024

Enrollment Period

1.2 years

First QC Date

April 8, 2021

Results QC Date

November 21, 2023

Last Update Submit

January 10, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Number of Participants Who Disclosed the Donor Conception to Their Children

    Participant's report of current state of disclosure to their child or children. Total score range = 1 (disclosed) 2 (not-disclosed)

    Disclosure assessed at 4-week time point. Data for the 12-week time point was missing due to a technology issue.

Secondary Outcomes (3)

  • Change in Disclosure Intention

    Baseline-Change in Disclosure Intention at Immediate posttest-Month 1-Month 3

  • Change in Disclosure Competence

    Baseline-Change in Disclosure Competence at Immediate posttest-Month 1-Month 3

  • Change in Disclosure Anxiety

    Baseline-Change in Disclosure Anxiety at Immediate posttest-Month 1-Month 3

Other Outcomes (3)

  • Acceptability of the TELL Tool and eBook

    Immediate posttest

  • Acceptability of the TELL Tool, eBook and Study Protocol

    Month 15

  • Pretesting of the Measures

    Before baseline

Study Arms (2)

TELL Tool Group

EXPERIMENTAL

Parents in the TELL Tool group will complete a decision support aid that has four interactive, multimedia and multicomponent modules that will be administered digitally. It will take parents about 60 minutes to complete the TELL Tool.

Behavioral: TELL Tool Intervention

eBook Attention-Control

ACTIVE COMPARATOR

Parents in the eBook attention-control group will complete one interactive, multimedia and multicomponent program that contains information about good parenting principles and is administered digitally. It will take parents about 60 minutes to complete the eBook attention control.

Behavioral: eBook Attention Control

Interventions

A 60-minute session with decision support information delivered digitally to parents at their homes or other private, quiet location.

Also known as: TELL Tool
TELL Tool Group

A 60-minute session with good parenting principles delivered digitally to parents at their homes or other private, quiet location.

Also known as: eBook
eBook Attention-Control

Eligibility Criteria

Age21 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Reside in the United States or one of its recognized territories
  • Conceived 1 or more children via gamete (egg/sperm) or embryo donation who are currently between the ages of 1 - 16 years of age
  • Have not informed their child(ren) about their donor conception origins
  • Are 21 years-of-age or older
  • English speaking
  • Active practice as a healthcare professional (e.g., nurse, physician, psychologist, social worker)
  • Provide education and/or counseling to gamete (eggs, sperm) and/or embryo donation recipient parents about disclosure to their children in the United States or one of its recognized territories
  • Able to provide feedback and insight about new tools to assist gamete (eggs, sperm) and/or embryo donation recipient parents with disclosure to their donor-conceived children
  • Are 21 years-of-age or older
  • English speaking

You may not qualify if:

  • Have already disclosed the donor conception to their donor-conceived child or children
  • Reside outside of the United States or one of its recognized territories
  • Not directly involved in providing education and/or counseling to gamete (eggs, sperm) and/or embryo donation recipient parents about disclosure to their children
  • Are a member of the research team

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Illinois at Chicago

Chicago, Illinois, 60605, United States

Location

MeSH Terms

Conditions

Infertility

Condition Hierarchy (Ancestors)

Genital DiseasesUrogenital Diseases

Results Point of Contact

Title
Patricia Hershberger
Organization
University of Illinois Chicago

Study Officials

  • Patricia Hershberger, PhD

    University of Illinois Chicago

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Masking Details
Parents will be randomized into two groups (either the TELL Tool group or the attention control eBook group) using a permuted block approach that is stratified by the age categories of the parent's children and using an online (REDCap) randomization module.
Purpose
OTHER
Intervention Model
PARALLEL
Model Details: Parent participants will be randomized to one of two groups: (1) TELL Tool group, or (2) eBook attention control group. Data will be collected at baseline, immediate posttest (post-TELL tool/post-eBook attention control) and at 2 additional time points (months 1 and 3)
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

April 8, 2021

First Posted

April 12, 2021

Study Start

July 26, 2021

Primary Completion

September 30, 2022

Study Completion

July 31, 2023

Last Updated

January 11, 2024

Results First Posted

January 11, 2024

Record last verified: 2024-01

Data Sharing

IPD Sharing
Will not share

When we publish our results, electronic copies of publications will be deposited in PubMed Central within four weeks of acceptance by a journal. We will also submit our results to ClinicalTrials.gov Protocol Registration and Results System as required.

Locations